# Gabapentin to Reduce Alcohol and Improve Viral Load Suppression

> **NCT05443555** · PHASE2 · RECRUITING · sponsor: **Boston Medical Center** · enrollment: 220 (estimated)

## Conditions studied

- HIV
- Heavy Drinking

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05443555
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2026-08
- **Final completion:** 2027-05
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443555, "Gabapentin to Reduce Alcohol and Improve Viral Load Suppression". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05443555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*